Figure 4: CHD1L inhibitors reverse EMT and the malignant phenotype in CRC.

Dose responses for CHD1L inhibitors that modulate EMT measured by high-content imaging of (A) downregulation of VimPro-GFP reporter and (B) Upregulation of EcadPro-RFP reporter. Data curves were fit using Log [CHD1L inhibitor] vs. variable slope (4 parameters) in GraphPad Prism. Mean EC₅₀ values ± SEM are calculated from three independent experiments (C) Representative images exhibiting reversion of EMT by compound 6 in SW620 tumor organoids measured by EMT reporter assays. (D) Western blot analysis showing protein expression changes of additional EMT biomarkers slug and ZO1. (E) CSC stemness measured by clonogenic colony formation after pretreatment with CHD1L inhibitors in DLD1^CHD1L-OE and HCT116 cells. (F) Inhibition of invasive potential of HCT116 cells after treatment of CHD1L inhibitors. Welch’s t-test statistical analysis was used to determine significance, where * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001.